Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high‐risk patients
暂无分享,去创建一个
E. Macintyre | O. Hermine | V. Asnafi | L. Lhermitte | F. Suarez | K. Beldjord | F. Lefrère | B. Varet | M. Rubio | C. Callens | M. Chandesris | C. Brouzes | C. Belanger | A. Bedin | F. Garnache Ottou | Marlene Garrido | Sarah Villemant | B. Deau | F. Lefrère
[1] Till Acker,et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Clappier,et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL , 2013, Leukemia.
[3] C. von Kalle,et al. BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.
[4] A Orfao,et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.
[5] J. Connors,et al. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. , 2012, Blood.
[6] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.
[7] D. Catovsky,et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant* , 2012, British journal of haematology.
[8] T. Haferlach,et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. , 2011, Blood.
[9] Mario Cazzola,et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. , 2012, Blood.
[10] H. Kantarjian,et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. , 2011, Blood.
[11] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[12] F. Ravandi. Chemo-immunotherapy for hairy cell leukemia , 2011, Leukemia & lymphoma.
[13] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[14] W. Klapper,et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.
[15] M. Djokic. Immunophenotypic Analysis of CD103+ B-Lymphoproliferative Disorders: Hairy Cell Leukemia and Its Mimics , 2010 .
[16] M. Stetler-Stevenson,et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. , 2009, Blood.
[17] A. Rohatiner,et al. Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.
[18] S. Tugulea,et al. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. , 2009, American journal of clinical pathology.
[19] J. Fehr,et al. Long‐term follow‐up of interferon‐alpha induction and low‐dose maintenance therapy in hairy cell leukemia , 2009, European journal of haematology.
[20] H. Kantarjian,et al. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy , 2009, Leukemia & lymphoma.
[21] N. Harris,et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. , 2008, Blood.
[22] S. Galimberti,et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow‐up , 2008, British journal of haematology.
[23] A. Gratwohl,et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98) , 2008, Haematologica.
[24] D. Weisenburger,et al. Hairy cell leukaemia: a heterogeneous disease? , 2008, British journal of haematology.
[25] Francesco Bertoni,et al. High density genome‐wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia , 2008, British journal of haematology.
[26] W. Klapper,et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations , 2008, Haematologica.
[27] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[28] K. Sułek,et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. , 2006, Blood.
[29] E. Matutes. Immunophenotyping and differential diagnosis of hairy cell leukemia. , 2006, Hematology/oncology clinics of North America.
[30] H. Kantarjian,et al. Eradication of minimal residual disease in hairy cell leukemia. , 2006, Blood.
[31] J. Sunshine,et al. Somatic hypermutation and VH gene usage in hairy cell leukaemia , 2006, British journal of haematology.
[32] I. Pastan,et al. Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction , 2006, Clinical Cancer Research.
[33] L. Peterson,et al. Immunophenotypic variations in hairy cell leukemia. , 2006, American journal of clinical pathology.
[34] D. Campana,et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR , 2005, British journal of haematology.
[35] S. Galimberti,et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia , 2004, European journal of haematology.
[36] H. Döhner,et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation , 2004, Leukemia.
[37] T. Haferlach,et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine , 2004, Leukemia.
[38] J. Delgado,et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. , 2004, Haematologica.
[39] J. Koziol,et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Glasmacher,et al. Advances in the treatment of hairy-cell leukaemia. , 2003, The Lancet. Oncology.
[41] M. Raffeld,et al. Minimal Residual Disease Detection in Hairy Cell Leukemia , 2003 .
[42] M. Raffeld,et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. , 2003, American journal of clinical pathology.
[43] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.
[44] H Clevers,et al. Leukocyte‐associated immunoglobulin‐like receptor‐1 (LAIR‐1) is differentially expressed during human B cell differentiation and inhibits B cell receptor‐mediated signaling , 1999, European journal of immunology.
[45] F. Behm,et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia , 1999, Leukemia.
[46] M. Grever,et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] L Meyaard,et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. , 1997, Immunity.
[48] D. Catovsky,et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up study , 1997, British journal of haematology.
[49] L. Peterson,et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. , 1996, Blood.
[50] A. Hagenbeek,et al. Detection of Minimal Residual Disease in Acute Leukemia by Flow Cytometry a , 1986, Annals of the New York Academy of Sciences.